Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates